Quantcast

Latest drug discovery Stories

2014-09-08 08:30:20

- Data show improvements in hemodynamic parameters and exercise capacity SAN DIEGO, Sept. 8, 2014 /PRNewswire/ -- Mast Therapeutics, Inc. (NYSE MKT: MSTX) today reported top-line results from a Phase 2 study of AIR001 (sodium nitrite) inhalation solution for the treatment of pulmonary arterial hypertension (PAH). Mast obtained the rights to the AIR001 program through its acquisition of privately-held Aires Pharmaceuticals, Inc. earlier this year. In the primary efficacy analysis...

2014-09-08 08:29:41

BERGEN, Norway, September 8, 2014 /PRNewswire/ -- BerGenBio AS ("BerGenBio" or the "Company"), an oncology biopharmaceutical company, today announces that the United States Patent and Trademark Office (USPTO) has issued United States Patent 8,735,064 covering a method for creating and identifying functional interference RNA (RNAi) molecules (1). RNAis are recombinant nucleic acid molecules that have the ability to specifically down-regulate an expressed target gene in vivo....

2014-09-05 08:23:23

MELBOURNE, Australia, Sept. 5, 2014 /PRNewswire/ -- Prana Biotechnology (ASX: PBT) has today announced the US Food and Drug Administration (FDA) has granted Orphan Drug designation to PBT2 for the treatment of Huntington Disease. Orphan drug designation is granted by the FDA to promote the development of drugs for diseases affecting less than 200,000 people in the United States. Orphan drug designation entitles Prana to seven years of market exclusivity for the use of PBT2 in the...

2014-09-04 08:30:35

ALBANY, N.Y., Sept. 4, 2014 /PRNewswire/ -- AMRI (NASDAQ: AMRI) announced today that it has expanded into the protein market, with an initial focus on protein expression and purification. The global revenue of the total proteomics market is anticipated to grow at a compound annual growth rate of about 4.1% to about $9.2 billion by 2018(1). AMRI's current and ongoing activities - as part of its New York State Public-Private Partnership in Buffalo, N.Y. - encompass the production of...

2014-09-03 08:33:44

Experienced Financial and Operational Leader to Support Global Development of Novel Monoclonal Antibody Therapeutics to GPCRs LA JOLLA, Calif. and SHANGHAI, Sept. 3, 2014 /PRNewswire/ -- RuiYi, Inc., a global therapeutic innovation leader, announced today the appointment of Mark Saad as chief financial officer (CFO). Mr. Saad is a skilled financial and operations leader and was most recently CFO at Cytori Therapeutics for the past ten years. At RuiYi, he will play a critical...

2014-09-03 08:32:32

- Infinity to Receive $275 Million Upfront Payment and $530 Million in Potential Milestones - CAMBRIDGE, Mass. and NORTH CHICAGO, Ill., Sept. 3, 2014 /PRNewswire/ -- Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) and AbbVie Inc. (NYSE: ABBV) today announced that they have entered into a global collaboration to develop and commercialize duvelisib (IPI-145), Infinity's oral inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma, for the treatment of patients with cancer....

2014-09-02 20:23:05

LONDON, Sept. 2, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report: Companion Diagnostics: Technologies and Marketshttps://www.reportbuyer.com/product/341176/Companion-Diagnostics-Technologies-and-Markets.html STUDY GOALS AND OBJECTIVESThis BCC Research report, Companion Diagnostics: Technologies and Markets, provides an overview of the current state of development in the companion diagnostics field, existing products on the market and detailed analysis of...

2014-09-02 08:30:12

Kyungpook National University Hospital in South Korea Treats the First Patient in the 14 Country, 100 Site Global Study LAWRENCEVILLE, N.J., Sept. 2, 2014 /PRNewswire/ -- Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced that the first patient has been enrolled in its pivotal Phase III OPTIMA Study of ThermoDox® in combination with optimized radiofrequency ablation (RFA) in patients with primary liver cancer, also known as hepatocellular...

2014-09-02 08:29:52

SAN DIEGO, Sept. 2, 2014 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that the US Food and Drug Administration (FDA) has granted orphan drug status to APD811 for the treatment of pulmonary arterial hypertension. "The FDA Office of Orphan Products Development (OOPD) evaluates scientific and clinical data submissions from sponsors to identify and designate drug candidates that could potentially treat rare diseases to help advance the evaluation and...

2014-09-02 08:29:23

ENGLEWOOD, Colo., Sept. 2, 2014 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announced an update on the phase III, multicenter, double-blind STEP study of Ampion(TM) for osteoarthritis of the knee. http://photos.prnewswire.com/prnvar/20120516/MM09116LOGO The STEP study enrolled 538 patients, 269 patients received Ampion(TM) and 269 patients received saline vehicle control. There were two primary endpoints: 1. Efficacy in reducing pain, as measured by the WOMAC A pain...


Word of the Day
tessitura
  • The prevailing range of a vocal or instrumental part, within which most of the tones lie.
This word is Italian in origin and comes from the Latin 'textura,' web, structure.